Objective: Evaluate the long-term outcomes of pleurectomy decortication, systemic chemotherapy and prophylactic radiotherapy in pleural mesothelioma (PM). Summary background data: There is no known cure for PM and cytoreductive surgery remains controversial. Methods: Retrospective analysis … More
Main Navigation Menu
➤ About the Law Offices of Thomas J. Lamb
PRACTICE AREAS
➤ Asbestos and Mesothelioma Claims
➤ Benzene Cancer and Disease Claims
➤ Pharmaceutical Drug Injury Lawsuits
➤ Breast Implants Lymphoma Cancer Lawsuits
➤ Free Case Evaluation by Lawyer Tom Lamb
INFORMATION
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Our "Recent Articles" Archives
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent Articles
Semaglutide: Eyesight Loss From Drug Side Effect NAION
Semaglutide eyesight loss from the drug side effect NAION is being investigated as possible drug injury lawsuits to be filed on behalf of patients against Novo Nordisk, the responsible drug company for Ozempic, Wegovy, and Rybelsus. The active ingredient for each of those three Novo Nordisk drugs … More
Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities
Mesothelioma is a malignant condition arising from the pleura and peritoneum that is closely related to asbestos exposure. Due to the prolonged time needed for one to fully develop mesothelioma, difficulty in diagnosing this condition early, its quick progression once manifested, and the limited … More
Depo-Provera Meningioma Increased Risk Warning in Europe
The European Medicines Agency (EMA) recommended a Depo-Provera meningioma increased risk warning in September 2024. One wonders why the FDA has not followed this EMA regulatory action. Therefore, the Depo-Provera drug label in the US still does not include a warning about the meningioma increased … More
Treatment of Pleural Mesothelioma: ASCO Guideline Update
Since the initial [American Society of Clinical Oncologists (ASCO)] clinical practice guideline on the treatment of malignant pleural mesothelioma (PM) was published in 2018 considerable progress has been made which has changed not only the management but even the name of this disease. This … More
Why Are There Depo-Provera Brain Tumor Warnings In Europe But Not US?
Depo-Provera brain tumor lawsuits for women who have been diagnosed with intracranial meningioma, a specific type of brain tumor, are being filed against the responsible pharmaceutical companies. A primary focus of these legal cases will be why the Depo-Provera drug label in the US does not include … More